2017
Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients?
Chagpar AB, Cicek AF, Harigopal M. Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients? The American Surgeon 2017, 83: 704-708. PMID: 28738939, DOI: 10.1177/000313481708300725.Peer-Reviewed Original ResearchConceptsBreast cancer patientsNegative marginsCancer patientsPrimary tumor markersInvasive tumor sizePrimary tumor tissuesMedian invasive tumor sizeInitial surgeryOccult cancerOccult diseaseProspective trialInitial resectionMultifocal diseasePartial mastectomyDuctal carcinomaTumor sizeCavity shavesStage 0Independent pathologistsTumor markersTissue microarrayFurther diseasePatientsTumor tissueDiseaseEconomic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals Of Surgery 2017, 265: 39-44. PMID: 27192352, PMCID: PMC5605915, DOI: 10.1097/sla.0000000000001799.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularConnecticutFemaleFollow-Up StudiesHealth ExpendituresHospital CostsHumansMargins of ExcisionMastectomy, SegmentalMiddle AgedProspective StudiesReoperationSingle-Blind MethodTreatment OutcomeConceptsCavity shave marginsStandard partial mastectomyPartial mastectomyRe-excision ratesIndex surgeryInitial surgeryBreast cancerHospital perspectiveLower re-excision ratesDirect hospital costsBreast cancer patientsOperating room timeReoperative surgeryBaseline characteristicsOperative timePositive marginsShave marginsCancer patientsHospital costsStage 0Room timeSurgeryPathology costsPatientsMastectomy
2015
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer
Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. New England Journal Of Medicine 2015, 373: 503-510. PMID: 26028131, PMCID: PMC5584380, DOI: 10.1056/nejmoa1504473.Peer-Reviewed Original ResearchConceptsCavity shave marginsPositive marginsPartial mastectomyShave marginsDuctal carcinomaBreast cancerInvasive cancerOutcome measuresStandard partial mastectomySecondary outcome measuresPrimary outcome measureLower ratesRoutine resectionMedian ageClinicopathological characteristicsCavity shavingMargin clearanceSecond surgeryInvasive carcinomaStage 0MastectomyPathological testingPatientsFurther diseaseVolume of tissue
2013
Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?
Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 344-348. PMID: 23910708, DOI: 10.1016/j.ijrobp.2013.05.052.Peer-Reviewed Original ResearchConceptsBreast conservation therapyEarly-stage breast cancer patientsHuman epidermal growth factor receptor 2Recurrence-free survivalBreast cancer patientsKi-67 expressionKi-67Clinicopathologic featuresConservation therapyCancer patientsIndependent associationLocoregional recurrence-free survivalDistant metastasis-free survivalLocal relapse-free survivalEpidermal growth factor receptor 2Univariate/multivariate analysisPrognostic clinicopathologic featuresCause-specific survivalHormone receptor statusGrowth factor receptor 2Metastasis-free survivalRelapse-free survivalKi-67 overexpressionSignificant independent associationKi-67 staining